The Use of Leukotriene Inhibitors as Basic Therapy in Children with Bronchial Asthma
DOI:
https://doi.org/10.48112/acmr.v3i2.31Keywords:
Leukotriene, Bronchial Asthma, Montelukast, Inflammatory, GlucocorticosteroidsAbstract
Abstract Views: 38
In the pharmacotherapy of bronchial asthma, a "step-by-step" approach is recommended, which includes an increase or decrease in the volume of therapy, depending on the severity of clinical symptoms. In complex therapy, it is possible to use non-drug methods of treatment, although the effectiveness of some of them is debatable and needs further study. To achieve this goal, children over the age of 3 years (the group of patients consisted of 26 children) with different forms and degrees of severity of bronchial asthma were included in the study. Patients of the main group took L-Montus (montelukast), children of the ketotifen comparison group. Leukotriene receptor antagonists (montelukast, zafirlukast) are the first mediator-specific therapy of AD and represent a new therapeutic class of drugs in the treatment of the disease. The effectiveness of leukotriene receptor antagonists has been proven in randomized clinical trials among adults and children with bronchial asthma. Leukotriene receptor blockers, in particular L-Montus relieves the symptoms of AD and is a drug for the basic therapy of this disease, leads to a significant improvement in control, reduces the frequency of exacerbations of AD caused by viral infection in children aged 3-5 years. It has an anti-inflammatory effect, complementary to the action of glucocorticosteroids.
References
Mason, J Van & Portnoy, J M . 2020. Immunologic strategies for prevention of asthma. J Allergy Clin Immunol Pract. 8(3):834–847.
Rai, SP, Patil, AP, Vardhan, V, Marwah, V, Pethe, M & Pandey, IM . 2007. Best Treatment Guidelines For Bronchial Asthma. Med J Armed Forces India. 63(3):264–268.
Guilbert, T W, Bacharier, L B & Fitzpatrick, A M . 2014. Severe asthma in children. J Allergy Clin Immunol Pract. 2(5):489–500.
Chung, K F, Wenzel, S E, Brozek, J L, Bush, A, Castro, M & Sterk, P J . 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 43(2):343–73.
Bousquet, J . 2000. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy. 30:2–5.
Veremchuk, L V, Yankova, V I, Vitkina, T I, Nazarenko, A V & Golokhvast, K S . 2016. Urban air pollution, climate and its impact on asthma morbidity. Asian Pac J Trop Biomed. 6(1):76–85.
Moorman, J E, Zahran, H, Truman, B I & Molla, M T . 2006. Centers for Disease Control and Prevention (CDC) MMWR Surveill Summ. 60:84–90.
Moonie, S A, Sterling, D A, Figgs, L & Castro, M . 2006. Asthma status and severity affects missed school days. J Sch Health. 76(1):18–24.
Lang, A, Carlsen, K H, Haaland, G, Devulapalli, C S, Munthe-Kaas, M, Mowinckel, P & Carlsen, K . 2008. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy. 63(8):1054–60.
Hirai, K, Tanaka, A, Homma, T, Kawahara, T, Oda, N & Mikuni, H . 2021. Prevalence and clinical features of Asthma-COPD overlap in patients with COPD not using inhaled corticosteroids. Allergol Int. 70(1):134–135.
Bellin, M H, Osteen, P, Kub, J, Bollinger, M E, Tsoukleris, M & Chaikind, L . 2015. Stress and Quality of Life in Urban Caregivers of Children With Poorly Controlled Asthma: A Longitudinal Analysis. J Pediatr Health Care. 29(6):536–346.
Godard, P, Chanez, P, Siraudin, L, Nicoloyannis, N & Duru, G . 2002. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 19(1):61–67.
Zahran, Hatice S., Bailey, Cathy M., Damon, Scott A., Garbe, Paul L. & Breysse, Patrick N. . 2018. Vital Signs: Asthma in Children — United States, 2001–2016. MMWR Morb Mortal Wkly Rep. 67(5):149–155.
Puig-Junoy, J & Pascual-Argente, N . 2009. Socioeconomic costs of asthma in the European Union, United States and Canada: A systematic review. Rev Esp Salud Publica. 91.
Bateman, E D, Hurd, S S, Barnes, P J, Bousquet, J, Drazen, J M & Fitzgerald, M . 2008. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 31(1):143–178.
Zyryanov, S K, Diyakov, I N & Avdeev, S N . 2020. Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation. FARMAKOEKONOMIKA. 12(4):268–78.
Lemanek, K . 1990. Adherence issues in the medical management of asthma. J Pediatr Psychol. 15(4):437–58.
Kohlboeck, G, Koletzko, S, Bauer, C P, Berg, Von, Berdel, A & Krämer, D . 2013. GINI-plus Study groups. Association of atopic and non-atopic asthma with emotional symptoms in school children. Pediatr Allergy Immunol. 24(3):230–236.
Goodwin, R D, Fergusson, D M & Horwood, L J . 2004. Asthma and depressive and anxiety disorders among young persons in the community. Psychol Med. 34(8):1465–1474.
Feldman, J M, Steinberg, D, Kutner, H, Eisenberg, N, Hottinger, K & Sidora-Arcoleo, K . 2013. Perception of pulmonary function and asthma control: the differential role of child versus caregiver anxiety and depression. J Pediatr Psychol. 38(10):1091–1100.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Advances in Clinical Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI-PMH 
